PMS-CYCLOPENTOLATE HCL OPH SOLUTION 1% 1 %
CYCLOPENTOLATE HYDROCHLORIDE : 1 % · DIN 00878189 · PHARMASCIENCE INC
Health Canada status: CANCELLED POST MARKET
What is PMS-CYCLOPENTOLATE HCL OPH SOLUTION 1%?
PMS-CYCLOPENTOLATE HCL OPH SOLUTION 1% 1 % contains CYCLOPENTOLATE HYDROCHLORIDE : 1 %. It is listed in the Health Canada Drug Product Database under DIN 00878189, held by PHARMASCIENCE INC, supplied as LIQUID for OPHTHALMIC administration. Health Canada currently lists it as cancelled post market, status dated 28-Oct-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00878189 |
|---|---|
| Brand name | PMS-CYCLOPENTOLATE HCL OPH SOLUTION 1% |
| Generic / active ingredient | CYCLOPENTOLATE HYDROCHLORIDE : 1 % |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 1 % |
| Dosage form | LIQUID |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01FA04 CYCLOPENTOLATE |
| AHFS class | 52:24.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Oct-2016 |
| Original market date | 1992-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code S01FA04 CYCLOPENTOLATE. 3 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYCLOGYL | 1 % | DROPS | ALCON CANADA INC | MARKETED | DIN 00252506 |
| MINIMS CYCLOPENTOLATE HYDROCHLORIDE | 1 % | SOLUTION | BAUSCH & LOMB INC | MARKETED | DIN 02148382 |
| ODAN-CYCLOPENTOLATE | 1 % | SOLUTION | ODAN LABORATORIES LTD | MARKETED | DIN 00626627 |
| CYCLOPENTOLATE | 0.5 % | SOLUTION | PHARMA STULLN INC. | CANCELLED POST MARKET | DIN 02023687 |
| CYCLOPENTOLATE | 1 % | SOLUTION | PHARMA STULLN INC. | CANCELLED POST MARKET | DIN 02023644 |
| DOM-CYCLOPENTOLATE HCL OPHTHALMIC SOLUTION-1% | 1 % | SOLUTION | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02181436 |
| MINIMS CYCLOPENTOLATE HYDROCHLORIDE | Strength | Solution | BAUSCH & LOMB INC 1400 N Goodman Street Rochester New York United States 14609 | DORMANT | DIN 02148331 |
| ODAN-CYCLOPENTOLATE | 0.5 % | SOLUTION | ODAN LABORATORIES LTD | DORMANT | DIN 00626635 |
Who else supplies CYCLOPENTOLATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CYCLOPENTOLATE appears in 24 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.